title: Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.
abstract: The majority of HIV-infected patients in developing countries commences combination antiretroviral therapy (cART) with advanced disease. We examined predictors of disease progression in patients initiating cART with CD4 count ≤200 cells/mm(3) in the TREAT Asia HIV Observational Database. The main outcome measure was progression to either an AIDS-defining illness or death occurring 6 months after initiation of cART. We used survival analysis methods. A total of 1255 patients contributed 2696 person years of follow-up; 73 were diagnosed with AIDS and 9 died. The rate of progression to the combined end point was 3.0 per 100 person years. The factors significantly associated with a higher risk of disease progression were Indian ethnicity, infection through intravenous drug use, lower CD4 count, and hemoglobin ≤130 g/dL at 6 months. In conclusion, measurements of CD4 count and hemoglobin at month 6 may be useful for early identification of disease progression in resource-limited settings.
authors: The Kirby Institute, University of New South Wales, Sydney, Australia. hbyakwaga@nchecr.unsw.edu.au
authors: H
authors: H
authors: Byakwaga
authors: K
authors: K
authors: Petoumenos
authors: J
authors: J
authors: Ananworanich
authors: F
authors: F
authors: Zhang
authors: M A
authors: MA
authors: Boyd
authors: T
authors: T
authors: Sirisanthana
authors: P C K
authors: PC
authors: Li
authors: C
authors: C
authors: Lee
authors: C V
authors: CV
authors: Mean
authors: V
authors: V
authors: Saphonn
authors: S F S
authors: SF
authors: Omar
authors: S
authors: S
authors: Pujari
authors: P
authors: P
authors: Phanuphak
authors: P L
authors: PL
authors: Lim
authors: N
authors: N
authors: Kumarasamy
authors: Y M A
authors: YM
authors: Chen
authors: T P
authors: TP
authors: Merati
authors: S
authors: S
authors: Sungkanuparph
authors: R
authors: R
authors: Ditangco
authors: S
authors: S
authors: Oka
authors: G
authors: G
authors: Tau
authors: J
authors: J
authors: Zhou
authors: M G
authors: MG
authors: Law
authors: S
authors: S
authors: Emery
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology*; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001208:Asia / Q000453:epidemiology; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D016208:Databases, Factual; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology*; D015497:HIV-1; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D015819:Substance Abuse, Intravenous / Q000453:epidemiology; D016019:Survival Analysis
chemical_list: D044966:Anti-Retroviral Agents; D006454:Hemoglobins
keywords: HIV; antiretroviral therapy; disease progression; resource-limited settings